Class summary at a glance.

Every drug in the Mood Stabilizer class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $550.4Mcombined across class
Total Rx claims: 9.7M1.7M unique beneficiaries
Generic mfrs (active): 42across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Divalproex

Brand: Depakote · 7.7M Part D claims (CY24) · 1.3M beneficiaries · First FDA approval: 1983-03-10

21 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.055

→

Avg plan cost$0.320

Part D spend $362.1M 6× spread, current vs floor

Class share

66%

of class CY24 spend

View profile →

Carbamazepine

Brand: Carbamazepin · 2.0M Part D claims (CY24) · 421K beneficiaries · First FDA approval: 1968-03-11

21 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.104

→

Avg plan cost$0.701

Part D spend $188.3M 7× spread, current vs floor

Class share

34%

of class CY24 spend

View profile →

Carbamazepine Er

— Part D claims (CY24) · First FDA approval: 2022-03-31

Brand-only (no generics)

Low NADAC$0.226

→

Avg plan cost$0.626

Part D spend — 3× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.